Browsing: Explores

Azitra, a biopharmaceutical company, is developing a clinically backed anti-aging ingredient with potential applications for post GLP-1 skin laxity. The ingredient, ATR-COSF, utilizes a novel supernatant formulation that contains an active recombinant human domain of the protein filaggrin (rHDfilaggrin) for cosmetic and skin care applications

Muna Al-Khaifi, GP Oncologist at Mount Sinai Hospital (Toronto), Sinai Health. This article summarizes the systematic review and meta-analysis by Lee and Hwang, which evaluated the effects of exercise interventions on fatigue, body composition, physical fitness, and circulating biomarkers in women with breast cancer during active treatment and after treatment completion. The review examines how stage-specific exercise programs…